Circulating hsa-miR-5096 predicts 18F-FDG PET/CT positivity and modulates somatostatin receptor 2 expression: a novel miR-based assay for pancreatic neuroendocrine tumors
- Bocchini, Martine
- Tazzari, Marcella
- Ravaioli, Sara
- Piccinini, Filippo
- Foca, Flavia
- Tebaldi, Michela
- Nicolini, Fabio
- Grassi, Ilaria
- Severi, Stefano
- Calogero, Raffaele Adolfo
- Arigoni, Maddalena
- Schrader, Joerg
- Mazza, Massimiliano
- Paganelli, Giovanni
DOIAbstract
Gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs) are rare diseases encompassing pancreatic (PanNETs) and ileal NETs (SINETs), characterized by heterogeneous somatostatin receptors (SSTRs) expression. Treatments for inoperable GEP-NETs are limited, and SSTR-targeted Peptide Receptor Radionuclide Therapy (PRRT) achieves variable responses. Prognostic biomarkers for the management of GEP-NET patients are required. 18F-FDG uptake is a prognostic indicator of aggressiveness in GEP-NETs. This study aims to identify circulating and measurable prognostic miRNAs associated with 18FFDG- PET/CT status, higher risk and lower response to PRRT
Add to ORKG